VA
PASG icon

Verdad Advisers’s Passage Bio PASG Stock Holding History

Verdad Advisers’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150K Buy
30,728
+8,600
+39% +$53.8K 0.14% 167
2026
Q1 		$174K Buy
+22,128
New +$229K 0.2% 138

Other funds holding PASG

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $291M AUM 19.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Verdad Advisers's PASG Position: Q2 2026 in Review

Verdad Advisers increased its Passage Bio (PASG) stake by 39% in Q2 2026, buying an estimated $53.8K and bringing the position to 30,728 shares worth $150K. The position accounts for 0.14% of the portfolio, ranked #167.

Verdad Advisers first reported a position in PASG in Q1 2026 and has held it in 2 quarters since. The position peaked at $174K in Q1 2026. 29 funds tracked by Wall St. Rank hold PASG as of Q2 2026.

  • Verdad Advisers held 30,728 shares of Passage Bio worth $150K as of Q2 2026.
  • Verdad Advisers bought 8,600 Passage Bio shares in Q2 2026, an estimated $53.8K.
  • Passage Bio made up 0.14% of Verdad Advisers's portfolio in Q2 2026, its #167 holding.
  • Verdad Advisers first reported a position in Passage Bio in Q1 2026 and has held it in 2 quarters since.
  • Verdad Advisers's Passage Bio position peaked at $174K in Q1 2026.
  • 29 funds tracked by Wall St. Rank held Passage Bio as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.